Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in
terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients …

Simple Summary As one of most malignant tumors in brain, glioblastoma (GBM) is lack of
effective treatment and the prognosis of GBM patients is still very poor despite accumulated …

In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the
treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical …

Introduction Glioblastoma multiforme (GBM) is the deadliest type of brain cancer with poor
response to the available therapies, mainly due to intrinsic resistance mechanisms …

Recent developments in pharmacogenomics have created opportunities for predicting
temozolomide response in gliomas. Temozolomide is the main first-line alkylating …

Simple Summary Epigenetic changes in a cell's genome can cause the inactivation of genes
and affect how tumours respond to chemotherapy. These epigenetic changes do not alter …

Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

Gemcitabine (GEM) repurposing for glioblastoma (GBM) therapy has been investigated as a
fast-track approach to circumvent the drug resistance mediated by the O 6-alkylguanine …

Background Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor, that
is refractory to standard treatment and to immunotherapy with immune-checkpoint inhibitors …

Abstract Human herpesvirus (HHV)‐6 and HHV‐7 have been detected in central nervous
system and glioma tissue, while their exact role in glioma remains uncertain. Omics profiles …